跳至主要内容
临床试验/NCT03679702
NCT03679702Unknown不适用

A Viveve Experience Normalizes Untreated Selective Serotonin Reuptake Inhibitor (SSRI) Sexuality Syndrome

Michael Krychman, MD2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2018年12月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
10
试验地点
2
主要终点
Safety - Adverse Events

研究概览

简要总结

A pilot study to investigate non-surgical treatment for women who suffer from sexual complaints secondary to SSRI Sexuality Syndrome.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Currently using SSRI for 3 months at a stable dose

排除标准

  • Pregnant, currently breastfeeding, or breast-fed within the last 6 months
  • Has any implantable electrical device that could potentially be affected by use of radiofrequency.

研究组 & 干预措施

Active treatment

Other

干预措施: Viveve System (Device)

结局指标

主要结局

Safety - Adverse Events

时间窗: baseline to 6 month

safety of treatment of female sexual dysfunction secondary to SSRI sexuality syndrome

次要结局

  • Female Sexual Function Index (FSFI)(baseline to 3 and 6 months)

研究者

发起方
Michael Krychman, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Michael Krychman, MD

Michael Krychman, MD

Southern California Center for Sexual Health and Survivorship Medicine

研究点 (2)

Loading locations...

相似试验